Rectal Cancer
Search for other papers by Roswell Park Cancer Institute in
Current site
Google Scholar
PubMed
In 2007, an estimated 41,420 new cases of rectal cancer will occur in the United States (23,840 cases in men; 17,580 cases in women). The guidelines for rectal cancer overlap considerably with those for colon cancer, and the panel unanimously endorses patient participation in a clinical trial over standard or accepted therapy in both. This is especially true for cases of advanced disease and for patients with locally aggressive colorectal cancer who are receiving combined modality treatment.
The latest updates of the NCCN Anal Carcinoma Clinical Practice Guidelines in Oncology are available online at www.nccn.org.
For the most recent version of the guidelines, please visit NCCN.org
Since 1898, Roswell Park Cancer Institute (RPCI), America's first cancer center, has forged an exemplary reputation based on the combined strength of basic/translational research, multidisciplinary oncology teams, educational programs, and compassionate staff. A seamless interface of scientific inquiry and clinical application and an aggressive clinical trials program afford patients access to promising breakthroughs in cancer diagnostics, technology, and therapies.
Over the past decade, RPCI has undergone major renovation and expansion, adding nearly 200 faculty, opening a new hospital facility and a $74 million Center for Genetics & Pharmacology, and forming strategic partnerships with investigators and centers throughout the nation. Committing the infrastructure, intellectual capital, and necessary resources to convert its scientific discoveries into real-world products/applications, RPCI has recently established 3 biotech spin-off companies. RPCI ranks among the nation's top 1% of cancer centers and teaching hospitals for patient satisfaction; and among the top research centers funded by the NCI/NIH.
Donald L. Trump, MD (second picture on the cover), President and CEO, is a practicing medical oncologist and an innovative researcher (his Vitamin D and prostate cancer studies are considered landmark). Dr. Trump was recently elected to the Board of Directors of the Association of American Cancer Institutes. Michael K. K. Wong, MD, PhD, FRCPC (third picture), serves as Medical Director of Clinical Drug Development and Medical Advisor to the Technology Transfer Office, and Kerry J. Rodabaugh, MD (with patient; fourth picture), is with the Department of Gynecologic Oncology.
© 2019-2024 National Comprehensive Cancer Network